Orthocell Ltd's (ASX:OCC) Paul Anderson discusses with Proactive positive nerve regeneration results one year on from a study testing its nerve repair candidate on quadriplegic patients. The regenerative medicine company conducted the first interim data readout of all patients in the CelGro® clinical trial 12 months after the study concluded. 25 out of 33, or 75.8%, of all nerve repairs that took place during the study resulted in functional recovery.
Orthocell thrilled with positive nerve regeneration results
Quick facts: Orthocell Ltd
Price: 0.51 AUD
Market Cap: $97.68 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE